kimmtrak
Generic: tebentafusp
kimmtrak: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Immunocore Holdings plc (IMCR) | Approved |
FDA Decisions
FDA_MeetingFollowing a recent consultation with the U.S. FDA, the TEBE-AM Phase 2/3 trial was converted into a single Phase 3 registrational trial for previously treated advanced cutaneous melanoma.(IMCR)
Frequently asked questions
Who is developing kimmtrak?
kimmtrak is being developed by Immunocore Holdings plc.
What is kimmtrak's latest FDA decision?
The most recent tracked FDA decision for kimmtrak is FDA_Meeting for Following a recent consultation with the U.S. FDA, the TEBE-AM Phase 2/3 trial was converted into a single Phase 3 registrational trial for previously treated advanced cutaneous melanoma..
Get deeper analysis on kimmtrak
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis